EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Sima Ehsani Chimeh
Sponsor
Lilly USA, LLC
Unit
Cancer Center Division